This group employed IMSA101, a small molecule and an analogue of cGAMP that is an agonist of STING (stimulator of interferon genes) and that induces a pro-inflammatory cytokine milieu in general and IL-18 secretion in particular and thereby enhances CART anti-tumor efficacy (Uslu et al., 2024) [98]. This evidence concerns the gene IL18 and neoplasm.